The findings and compounds presented herein represent a therapeutic strategy to treat over 125,000 cancer patients annually carrying the p53 Y220C mutation (9) and as a prophylactic therapy to lower the cancer risk in Li-Fraumeni syndrome. Here, TP53 is linked to Li-Fraumeni syndrome.